 |
0 Diseases |  |
137 Trials |
|
137 Trials |  |
5343 News |  |
| «12...1213141516171819202122...9091» |
- | levofloxacin / Generic mfg.
Journal: Effects of Nanobubbles on Photochemical Processes of Levofloxacin Photosensitizer. (Pubmed Central) - Apr 3, 2024
The mechanism elucidated herein sheds light on how N2-NBs intricately influence both electron-transfer and energy-transfer reactions in the photosensitizer LEV. These findings not only contribute to a nuanced understanding of the underlying processes but also furnish novel insights that may inform the application of NBs in the realm of photodynamic therapy.
- | ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg.
Journal: Differential impacts of DNA repair machinery on fluoroquinolone persisters with different chromosome abundances. (Pubmed Central) - Apr 2, 2024
Here, we explore how an under-appreciated phenotypic variable, chromosome copy number (#Chr), influences the DNA repair systems persisters use to survive fluoroquinolone treatments. We found that #Chr significantly biases the DNA repair systems used by persisters, which suggests that #Chr heterogeneity should be considered when devising strategies to eradicate these troublesome bacterial variants.
- | levofloxacin / Generic mfg., azithromycin / Generic mfg., colistin sulphate / Generic mfg.
Journal, Combination therapy: The Potentiation Activity of Azithromycin in Combination with Colistin or Levofloxacin Against Pseudomonas aeruginosa Biofilm Infection. (Pubmed Central) - Apr 2, 2024
For CRPAO1 biofilm, only azithromycin-colistin combination and colistin monotherapy eradicated the bacteria in 60% and 40% of mice at the 6th day. Azithromycin-based combinations containing levofloxacin or colistin had no synergistic effect in vitro, and they are promising for clinical applications due to the good synergistic activity against PAO1 biofilms in vivo.
- ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg., moxifloxacin intravenous / Generic mfg.
Clinical and HLA associations of fluoroquinolone induced liver injury: results from the drug induced liver injury network (DILIN) (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1839;
Fluoroquinolone-induced liver injury typically presents with a short latency, variable pattern of liver injury, and carries a significant risk of chronicity and mortality. There is a significant association with HLA-DQA1*03:01 and HLA B*57:01.
- | Observational data, Journal: Antimicrobial resistance burden pre and post-COVID-19 pandemic with mapping the multidrug resistance in Egypt: a comparative cross-sectional study. (Pubmed Central) - Mar 31, 2024
While E.coli susceptibility has increased to cefoxitin, levofloxacin, and ciprofloxacin...baumannii resistance has increased more than double against ceftazidime, cefepime, and piperacillin-tazobactam (P?<?0.001). MRSA reserved its susceptibility to vancomycin and linezolid...XDR K. pneumoniae and A. baumannii have increased
- | Invanz (ertapenem) / Merck (MSD)
Journal: First Report and Characterization of a Plasmid-Encoded blaSFO-1 in a Multi-Drug-Resistant Aeromonas hydrophila Clinical Isolate. (Pubmed Central) - Mar 28, 2024
This is the first report of beta-lactamase SFO-1 within a clinical strain of Aeromonas. Due to the remarkable sequence identity of pMAH4 to plasmids associated with Enterobacterales genera like Klebsiella and the extensive capabilities of Aeromonas for horizontal gene transfer, our identification of a clinical isolate encoding SFO-1 on a plasmid suggests antibiotic resistance gene mobility between Enterobacterales and non-Enterobacterales species.
- | levofloxacin / Generic mfg., moxifloxacin intravenous / Generic mfg.
Journal: Predictors of Successful First-Line Helicobacter pylori Eradication with Fluoroquinolones in Pakistan: A Prospective Exploration of Demographic and Clinical Factors. (Pubmed Central) - Mar 27, 2024
Patients with comorbidities, excluding diabetes and hypertension (COR: 4.432, p = 0.019), dyspepsia (COR: 0.178, p < 0.001), and moxifloxacin triple therapy (COR: 0.194, p = 0.000), exhibited higher chances of eradication (p < 0.05). Further research is vital for tailored approaches to enhance eradication success.
- | levofloxacin / Generic mfg.
Journal: First reported human case of isolation of Vagococcus fluvialis from the urine of a former zoo clerk in Japan: a case report. (Pubmed Central) - Mar 26, 2024
Vagococcus spp. is commonly isolated from fish or animals, and based on the patient's work history, it is possible that the patient was a carrier because of transmission from animals.
- | Reimbursement, US reimbursement, Journal, Medicaid: Decreases and Pronounced Geographic Variability in Antibiotic Prescribing in Medicaid. (Pubmed Central) - Mar 25, 2024
This study identified sizable disparities by geography in the prescribing rates of eight antibiotics with over three-fold state-level differences. Areas with high prescribing rates, particularly for outpatients, may benefit from stewardship programs to reduce potentially unnecessary prescribing.
- | Journal: The Prevalence, Risk Factors, and Antimicrobial Resistance Determinants of Helicobacter pylori Detected in Dyspeptic Patients in North-Central Bangladesh. (Pubmed Central) - Mar 25, 2024
Amino acid substitutions in PBP-1A (T556S) and GyrA (N87K and D91N) and a 200 bp deletion in rdxA were detected in samples from some patients with recurrence after treatment with amoxicillin, levofloxacin, and metronidazole, respectively. The present study describes the epidemiological features of H. pylori infection in the area outside the capital in Bangladesh, revealing the spread of AMR-associated mutations.
- || Review: An overview of case reports and case series of pulmonary actinomycosis mimicking lung cancer: a scoping review. (Pubmed Central) - Mar 25, 2024
Radiological techniques are helpful but have limitations that can lead to unnecessary surgeries when confusing PA with lung cancer. Therefore, it is important to raise awareness about the signs and symptoms of PA and lung cancer to prevent undesirable complications and ensure appropriate treatment measures are taken.
- | Journal: Incidence of blood culture-related sepsis in neonates and antibiotics sensitivity of implicated organisms in a secondary healthcare facility in Ghana. (Pubmed Central) - Mar 24, 2024
Late-onset sepsis is a common sepsis category, and the implicated microorganisms are resistant to commonly prescribed antibiotics. This work was funded by Upper East Regional Hospital, Bolgatanga.
- | Invanz (ertapenem) / Merck (MSD)
Journal: Prevalence and Characteristics of Ertapenem-Mono-Resistant Isolates among Carbapenem-Resistant Enterobacterales in China. (Pubmed Central) - Mar 22, 2024
These findings illustrate that ETP-mono-resistant CRE strains are relatively prevalent and that caution should be exercised when using meropenem alone for treatment. The detection of carbapenemase should be prioritized.
- | levofloxacin / Generic mfg., rifampicin / Generic mfg.
Preclinical, Journal: Implant retention in a rabbit model of fracture-related infection. (Pubmed Central) - Mar 22, 2024
The duration of the infection from one to four weeks does not impact the success of infection clearance in this model. Bone healing, however, is impaired as the duration of the infection increases.
- Age-related features of the microbial flora in pediatric patients with cystic fibrosis in the Moscow region (Exhibition and Poster Area) - Mar 22, 2024 - Abstract #ECFS2024ECFS_464;
Bone healing, however, is impaired as the duration of the infection increases. The sensitivity of Staphylococcus aureus to macrolides decreases with age: to erythromycin from 34.6% at the age of 0
- Cayston (aztreonam lysine) / Gilead
Colonisation of a 4-month-old cystic fibrosis child by Burkholderia cenocepacia : treatment adaptation after relapse and strains genomic comparison (Exhibition and Poster Area) - Mar 22, 2024 - Abstract #ECFS2024ECFS_441;
Despite the lack of treatment guideline, cotrimoxazole, ceftazidime and meropenem are considered as useful molecules. Regardless of natural resistances to aztreonam and tobramycine, these molecules were used in relay of IV antibiotics and no relapse was observed since September 2023 until now.
- ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg.
Normobaric oxygen therapy augments killing of slow growing Pseudomonas aeruginosa by quinolones (Hall 1) - Mar 22, 2024 - Abstract #ECFS2024ECFS_305;
This proof-of-principle study demonstrates that reoxygenation of the infectious microenvironment by NBOT can significantly enhance the susceptibility of Pa to quinolones. Direct measurement of O 2 consumption in sputum samples can be considered for obtaining proof-of-concept for the advantageous use of adjuvant intermittent NBOT in adult pwCF.
- | Journal: High prevalence of ST5-SCCmec II-t311 clone of methicillin-resistant Staphylococcus aureus isolated from bloodstream infections in East China. (Pubmed Central) - Mar 20, 2024
Moreover, MRSA ST59 clone shows an upward trend and has begun to spread into hospitals. Our findings highlight the importance of epidemiological studies of S. aureus carriage in the eastern region.
- | Baxdela (delafloxacin) / Menarini, Melinta Therap
Preclinical, Retrospective data, Journal: Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections: a CRIOGO multicentre retrospective study. (Pubmed Central) - Mar 20, 2024
Despite the absence of breakpoints for S. epidermidis, delafloxacin may be an option for the treatment of complex BJI, including strains with MICs of ?0.094?mg/L, leading to 64% susceptibility. This study underlines the importance for determining specific S. epidermidis delafloxacin breakpoints for the management of BJI on material.
- | Journal: Analysis of carbapenem-resistant Acinetobacter baumannii carbapenemase gene distribution and biofilm formation. (Pubmed Central) - Mar 20, 2024
This study underlines the importance for determining specific S. epidermidis delafloxacin breakpoints for the management of BJI on material. The clinical strains have a high resistance rate to carbapenems, and the CRAB with blaOXA-51 and blaOXA-23 genes has a high resistance to antibiotics and a strong biofilm.
- | levofloxacin / Generic mfg.
Journal: Biogenic synthesis of levofloxacin-loaded copper oxide nanoparticles using Cymbopogon citratus: A green approach for effective antibacterial applications. (Pubmed Central) - Mar 19, 2024
LFX-loaded CuO NPs antibacterial activity was observed higher than plant extract, bare CuO NPs, and standard drug (Levofloxacin). This study provides a novel approach for the fabrication of biogenic CuO NPs with antibacterial drug levofloxacin and their usage as nano antibiotic carriers against pathogenic bacteria, especially antibiotic-resistant microbes.
- levofloxacin / Generic mfg.
Evaluation of an intervention to decrease length of stay in children with low-risk febrile neutropenia (Convention Center Exhibit Hall) - Mar 16, 2024 - Abstract #PAS2024PAS_2860;
This study provides a novel approach for the fabrication of biogenic CuO NPs with antibacterial drug levofloxacin and their usage as nano antibiotic carriers against pathogenic bacteria, especially antibiotic-resistant microbes. Cumulative antibiotic use between the pre- and post-intervention groups was statistically insignificant (median 13.5 [IQR 22.8,8] vs. 14 [IQR 22,9] days, P = 0.537), whereas Levofloxacin use was significantly longer in the post-intervention cohort versus the pre-intervention cohort (median 0 [IQR 0,4] vs. 0 [IQR 0,0] days, P = 24 hours
- | Enrollment open: INSPIRE-CODA: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis?Contezolid, Delamanid and Bedaquiline Cohort (clinicaltrials.gov) - Mar 15, 2024
P3, N=186, Recruiting, Sponsor: Beijing Chest Hospital
Cumulative antibiotic use between the pre- and post-intervention groups was statistically insignificant (median 13.5 [IQR 22.8,8] vs. 14 [IQR 22,9] days, P = 0.537), whereas Levofloxacin use was significantly longer in the post-intervention cohort versus the pre-intervention cohort (median 0 [IQR 0,4] vs. 0 [IQR 0,0] days, P = 24 hours Not yet recruiting --> Recruiting
- Mycobutin (rifabutin) / Pfizer, Lupin
COMPARISON OF EMPIRICAL THERAPY VERSUS SUSCEPTIBILITY TESTING-GUIDED THERAPY FOR REFRACTORY HELICOBACTER PYLORI INFECTION: A MULTICENTER, OPEN-LABEL, RANDOMIZED CONTROLLED, NON-INFERIORY TRIAL (Ballroom A - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_8306;
The difference of eradication rate between the MTGT and STGT groups was 0% (95% CI: -8.7%-8.7%, non-inferiority p-value=0.045) by ITT analysis, and was -1.9% (95% CI: -10.5%-6.7%, non-inferiority p-value=0.087) by PP analysis. Conclusions : Optimized empirical therapy was not inferior to susceptibility testing guided therapy for refractory H. pylori infection.
- Takecab (vonoprazan) / Takeda, Phathom Pharma
VONOPRAZAN-BASED DUAL AND TRIPLE THERAPY VERSUS BISMUTH-BASED QUADRUPLE THERAPY AS FIRST-LINE THERAPY FOR HELICOBACTER PYLORI INFECTION IN CHINA: A THREE-ARMED, RANDOMIZED CLINICAL TRIAL (140AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4461;
Conclusions : Optimized empirical therapy was not inferior to susceptibility testing guided therapy for refractory H. pylori infection. Between May 2022 and August 2023, treatment-na
- piperacillin sodium/tazobactam sodium / Generic mfg., levofloxacin / Generic mfg.
ANTIBIOTIC PROPHYLAXIS IN GASTRIC PER-ORAL ENDOSCOPIC PYLOROMYOTOMY: A PILOT STUDY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3535;
Conclusions Given the rise of bacterial resistance to antibiotics and the patient-reported adverse effects or allergies to antibiotics, this study supports that providers can consider avoiding perioperative antibiotics and postoperative antibiotics for healthy patients undergoing G-POEM. Patients with diabetes are often relatively immunocompromised and likely benefit from some antibiotics perioperatively, however, the exact course should be further explored.
- Mycobutin (rifabutin) / Pfizer, Lupin
EVALUATING THE POTENCY OF RESCUE ANTIBIOTICS AGAINST EMERGING ANTIBIOTIC RESISTANCE IN CLINICAL ISOLATES (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_998;
The potency of RFB, and FUR against multidrug resistant clinical strains was satisfactory. Also, results suggest that if patients do not respond to LVF including regimen, further treatment with same group antibiotics such as CIP, and MOX might need to be carefully considered.
- levofloxacin / Generic mfg., clarithromycin / Generic mfg.
TAILORED THERAPY GUIDED BY GENOTYPIC RESISTANCE BASED ON GASTRIC MUCOSAL SPECIMENS IN THE FIRST-LINE TREATMENT OF HELICOBACTER PYLORI INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_996;
Tailored therapy guided by genotypic resistance based on gastric mucosal specimens shows satisfactory eradication efficacy in the first-line treatment of H. pylori infection, which is superior to empirical therapy, whereas safety and patient compliance are comparable. Health economics need to be explored in more high-quality studies.
- clarithromycin / Generic mfg.
QUADRUPLE AND DUAL THERAPIES ARE SUPERIOR TO STANDARD CLARITHROMYCIN-BASED TRIPLE THERAPY FOR HELICOBACTER PYLORI FIRST-LINE ERADICATION THERAPY USED IN THE LATIN AMERICAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-LATAMREG). (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_994;
In Latin America, quadruple and dual therapies were superior to SCTT and were safer than standard triple therapy. SCTT should not be considered as a first-line eradication treatment in Latin America.
- ERADICATION RATES OF EMPIRIC HELICOBACTER PYLORI TREATMENT REGIMENS IN A U.S. SAFETY-NET POPULATION (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_990;
SCTT should not be considered as a first-line eradication treatment in Latin America. Overall, all commonly used empiric regimens had eradication success rates of 90%.
- EPIDEMIOLOGY AND ANTIBIOTIC RESISTANCE PATTERN OF HELICOBACTER PYLORI INFECTION IN SOUTH EAST ASIA COUNTRIES: A SYSTEMATIC REVIEW WITH META-ANALYSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_986;
Over the past decades (2000-2010 vs. 2011-2023), primary resistance has increased significantly for clarithromycin and levofloxacin (11%, 95% CI; 7%-14% vs. 27%, 95%CI; 19-35%, p-value=0.006, 7%, 95% CI; 4%-11% vs. 28%, 95%CI; 22-34%, p-value<0.001, respectively) while remaining relatively stable for metronidazole, amoxicillin and tetracycline. CONCLUSIONS : The increasing prevalence of antibiotic resistance in H. pylori necessitates an adaptation of treatment guidelines to address the needs for the tailored therapeutic approaches and the incorporation of antibiotic susceptibility testing in the future.
- Takecab (vonoprazan) / Takeda, Phathom Pharma
EXCELLENT ERADICATION RATE OF ONCE-DAILY VONOPRAZAN LEVOFLOXACIN-BASED QUADRUPLE THERAPY FOR H. PYLORI INFECTION IN HIGH CLARITHROMYCIN RESISTANCE AREA: A PROSPECTIVE RANDOMIZED STUDY (ONCE-VONO TRIAL) (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_984;
Once-daily 14-day vonoprazan, levofloxacin, clarithromycin-MR, and bismuth regimens provided excellent eradication rates. This regimen could be safely used as an alternative first-line treatment for H. pylori infection especially in high clarithromycin resistance area.
- Mycobutin (rifabutin) / Pfizer, Lupin
REAL-WORLD EFFICACY OF SECOND-LINE THERAPIES FOR HELICOBACTER PYLORI: A POPULATION-BASED STUDY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_982;
Concomitant quadruple containing AMO, levofloxacin(LEV) and tetracycline (TET) had emerged as the commonest regime recently (from 0.8% in 2003-2006 to 38.4% in 2015-2018)...Rifabutin containing regime had success rate over 82%...Conclusion : BIS quadruple therapy was the most effective second-line regimen for H. pylori with consistently stable success rate in this real-world study from Asia. Although retreatment with CLA containing triple therapies had a very low success rate, they were still commonly used as second-line therapy.
- levofloxacin / Generic mfg., clarithromycin / Generic mfg.
UPPER GASTROINTESTINAL ENDOSCOPY COMBINED WITH GASTRIC JUICE ANALYSIS BY THE MEDICAL DEVICE ENDOFASTER FOR REAL-TIME ASSESSMENT OF H. PYLORI INFECTION AND MOLECULAR-BASED ANTIBIOTIC RESISTANCE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_980;
Conclusion Molecular AST performed in gastric aspirate is highly accurate in the detection of H. pylori resistance to clarithromycin and levofloxacin and is comparable to conventional phenotypic AST. GM-AST in conjunction with the intraprocedural diagnosis of H. pylori is a valid tool for selecting tailored eradication regimens for the individual patient .
- levofloxacin / Generic mfg., clarithromycin / Generic mfg.
ASSESSING GENOTYPIC RESISTANCE OF CLARITHROMYCIN AND LEVOFLOXACIN IN PATIENTS WITH H. PYLORI INFECTION: COMPARATIVE ANALYSIS OF GASTRIC MUCOSA, GASTRIC JUICE, AND FECAL SAMPLES (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_977;
Remarkable consistency was observed between PCR results from gastric mucosa and gastric juice. However, the lower DNA extraction rate compromised the detection performance of fecal samples.
- Mycobutin (rifabutin) / Pfizer, Lupin
AGREEMENT BETWEEN STOMACH BIOPSY CULTURE AND STOOL NEXT-GENERATION SEQUENCING FOR DETERMINING HELICOBACTER PYLORI ANTIBIOTIC SUSCEPTIBILITY PROFILES IN A SCREENING PREDOMINANTLY HISPANIC U.S. POPULATION (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_976;
The level of agreement in H. pylori resistance between biopsy culture and stool NGS was substantial for levofloxacin and low for clarithromycin and metronidazole. Studies are ongoing comparing the two tests to better optimize stool NGS for convenient susceptibility profiling.
- levofloxacin / Generic mfg., clarithromycin / Generic mfg.
HELICOBACTER PYLORI TREATMENT, FOLLOW-UP AND OUTCOMES IN A PREDOMINANTLY HISPANIC POPULATION IN THE UNITED STATES (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_973;
Majority were Hispanic (63.4%). Patients were empirically treated with PAC (967, 76.8%), Bismuth-based quadruple therapy (PBMT) (115, 9.1%), or Levofloxacin-based triple therapy (PAL) (104, 8.3%).
- Quantification of antibiotic resistance and biofilm formation of explanted penile prosthesis bacterial isolates (221B) - Mar 12, 2024 - Abstract #AUA2024AUA_1173;
Given the strong biofilm-forming capacity of nearly all isolates, infections may occur from an imbalance of symbiotic and dysbiotic bacteria, rather than lack of eradication of biofilm. Further research is required to optimize prophylactic strategies.
- | levofloxacin / Generic mfg., norfloxacin / Generic mfg., ibuprofen / Generic mfg.
Journal: Coated Cotton Fabrics with Antibacterial and Anti-Inflammatory Silica Nanoparticles for Improving Wound Healing. (Pubmed Central) - Mar 12, 2024
The functionalized nanoparticles and textiles have been treated with model proteases for the in situ release of the drugs by the amide bond enzymatic cleavage. Topical dermal applications in medical bandages are expected, which favor wound healing.
- || Trial completion date, Trial primary completion date: DRAMATIC: Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB (clinicaltrials.gov) - Mar 11, 2024
P2, N=220, Recruiting, Sponsor: Boston University
Topical dermal applications in medical bandages are expected, which favor wound healing. Trial completion date: Jul 2025 --> May 2027 | Trial primary completion date: Jul 2025 --> May 2027
- | levofloxacin / Generic mfg.
Journal: The effect and mechanism of variable particle size microplastics and levofloxacin on the neurotoxicity of Rana nigromaculata based on the microorganism-intestine-brain axis. (Pubmed Central) - Mar 11, 2024
Trial completion date: Jul 2025 --> May 2027 | Trial primary completion date: Jul 2025 --> May 2027 The results of the targeted metabolism of neurotransmitters in the intestine suggest that in the LVFX-MP2 treatment, LVFX alleviated the intestinal microbiota disorder caused by 1.00
- | ciprofloxacin oral / Generic mfg.
Journal: Antibiotic susceptibility and genomic analysis of ciprofloxacin-resistant and ESBLs-producing Escherichia coli in vegetables and their irrigation water and growing soil. (Pubmed Central) - Mar 11, 2024
In conclusion, our research highlights the widespread presence of CIPRE. coli in irrigation water and thoroughly examines the genetic characteristics of CIPR-ESBLs-producing E. coli strains, underlining the need for ongoing monitoring and management to reduce multidrug-resistant bacteria in vegetables and their environment.
- | levofloxacin / Generic mfg.
Journal: Cu2O/WO3 S-scheme heterojunctions for photocatalytic degradation of levofloxacin based on coordination activation. (Pubmed Central) - Mar 11, 2024
It is witnessed that the C-N of piperazine ring and CO of carboxylic acid in LVX are coordinated with W5+ sites to build the electronic bridge to activate LVX, greatly promoting the further degradation. This work highlights the important role of selective coordination activation cooperated with S-type heterojunctions for the photocatalytic degradation and offers a new view to understand the degradation of antibiotics at molecular level.
- | Invanz (ertapenem) / Merck (MSD)
Journal: Multi-drug-resistant Escherichia coli in adult male patients with enlarged prostate attending general hospitals in Benue state. (Pubmed Central) - Mar 11, 2024
They had intL and gyrA genes, which are integron, and quinolone resistance genes and sul1 and sul2 which are sulphonamide resistance-associated genes. Levofloxacin, ertapenem, and Augmentin (100% susceptibilities) were considered choice drugs for treatment of Escherichia coli infection in patients with elevated PSA.
- | Journal: Isolation, Identification, Antimicrobial Resistance, Genotyping, and Whole-Genome Sequencing Analysis of Salmonella Enteritidis Isolated from a Food-Poisoning Incident. (Pubmed Central) - Mar 8, 2024
According to the genetic makeup of strain 21A, the change G > A was found to be the most common variation. We have comprehensively analyzed the genomic characteristics, drug resistance phenotype, virulence phenotype, and genetic evolution relationship of S. Enteritidis strain 21A, which will contribute towards an in-depth understanding of the pathogenic mechanism of S. Enteritidis and the effective prevention and control of foodborne diseases.
- | levofloxacin / Generic mfg.
Retrospective data, Journal: Summary of the clinical characteristics of tuberculous otitis media (Pubmed Central) - Mar 8, 2024
Meanwhile, multiple laboratory examination methods?such as T-spot and PCR? should be integrated synchronously to help support the diagnosis.
- | Observational data, Journal: Efficacy and tolerability of Helicobacter pylori eradication regimes in South Kivu, Eastern of the Democratic Republic of Congo: A single center observational study. (Pubmed Central) - Mar 8, 2024
should be integrated synchronously to help support the diagnosis. The study enrolled patients with evidence of H. pylori infection in histological examination or serology testing combined with a positive fecal antigen test.
- levofloxacin / Generic mfg.
Tuberculosis in pediatric kidney transplant recipients: 35 years of experience (MON-260; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1558;
Pulmonary tuberculosis was the most frequent clinical manifestation. There were no complications related to the kidney graft.Suspicion, early diagnosis, close follow-up, as well as contact study are a priority to avoid the spread of TB and ensure favorable results in this population.
- imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Antimicrobial Susceptibility of Klebsiella Pneumoniae Clinical Isolates From the Lower Respiratory Tract Infection During the COVID-19 Pandemic in Brazil (SMART 2020-2021) () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1822;
This study highlights an elevated prevalence of KPC-producing K. pneumoniae from the LRTI in Brazil, which underscores the urgent need to implement strategies to combat antimicrobial resistance. Furthermore, IMR is a new antibiotic that maintains high in vitro activity even in resistant isolates and can serve as another important treatment option for pneumonia caused by K. pneumoniae .
- ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg., azithromycin / Generic mfg.
Frequency and Severity of Myasthenia Gravis Exacerbations Associated with the Use of Ciprofloxacin, Levofloxacin, and Azithromycin (Colorado Convention Center | Bluebird 2E-H) - Mar 8, 2024 - Abstract #AAN2024AAN_2890;
Analysis of a large group of MG patients reveal that the usage of ciprofloxacin, levofloxacin or azithromycin resulted in MG exacerbation in a minority of patients. MG patients with recent hospitalization or ED visit appear to be at higher risk.